Compare ACHR & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACHR | TVTX |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 5.3B |
| IPO Year | 2020 | 2013 |
| Metric | ACHR | TVTX |
|---|---|---|
| Price | $5.53 | $65.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $12.00 | ★ $40.62 |
| AVG Volume (30 Days) | ★ 23.6M | 1.2M |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 30.28 | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $300,000.00 | N/A |
| Revenue This Year | $4,986.67 | $44.76 |
| Revenue Next Year | $876.87 | $35.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.30 | $22.06 |
| 52 Week High | $14.62 | $68.73 |
| Indicator | ACHR | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.19 | 57.68 |
| Support Level | $4.87 | $53.76 |
| Resistance Level | $5.59 | N/A |
| Average True Range (ATR) | 0.22 | 2.12 |
| MACD | -0.08 | -0.32 |
| Stochastic Oscillator | 11.88 | 53.71 |
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner. The company is building a platform to deliver aircraft, technologies, and services to customers world-wide across commercial and defense sectors.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.